(Q42603936)

3 November 2017

Pharmacokinetics of sapropterin in patients with phenylketonuria (English)

1 reference

3 November 2017

1 reference

1 reference

1 reference

François Feillet

1

1 reference

3 November 2017

Lorne Clarke

2

1 reference

3 November 2017

Concetta Meli

3

1 reference

3 November 2017

Mark Lipson

4

1 reference

3 November 2017

Andrew A Morris

5

1 reference

3 November 2017

Paul Harmatz

6

1 reference

3 November 2017

Diane R Mould

7

1 reference

3 November 2017

Bruce Green

8

1 reference

3 November 2017

Alex Dorenbaum

9

1 reference

3 November 2017

Marcello Giovannini

10

1 reference

3 November 2017

Erik Foehr

11

1 reference

3 November 2017

Sapropterin Research Group

12

1 reference

3 November 2017

1 January 2008

1 reference

Clinical Pharmacokinetics

3 November 2017

1 reference

3 November 2017

47

1 reference

3 November 2017

817-825

1 reference

3 November 2017

12

1 reference

https://scigraph.springernature.com/pub.10.2165/0003088-200847120-00006

3 November 2017

0 references

cites work

Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin

1 reference

12 December 2020

Prospective evaluation of a D-optimal designed population pharmacokinetic study.

1 reference

12 December 2020

Analysis of reduced forms of biopterin in biological tissues and fluids

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

1 reference

12 December 2020

Biopterin responsive phenylalanine hydroxylase deficiency

1 reference

12 December 2020

The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study

1 reference

12 December 2020

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

12 December 2020

Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration

1 reference

12 December 2020

Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy.

1 reference

12 December 2020

Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study

1 reference

12 December 2020

Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria

1 reference

12 December 2020

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

12 December 2020

Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria

1 reference

12 December 2020

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

12 December 2020

Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

1 reference

12 December 2020

Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences

1 reference

12 December 2020

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

1 reference

12 December 2020

10.2165/0003088-200847120-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

3 November 2017

0 references

1 reference